BACKGROUND Serum cholesterol efflux capacity, a biomarker that integrates contributors and modulators of the initial step of the reverse cholesterol transport, has been associated with atherosclerosis independently of high-density lipoprotein (HDL) cholesterol level.
L ow circulating levels of high-density lipoprotein (HDL) cholesterol represent a strong, independent risk factor for premature atherosclerosis and coronary heart disease (1) . Although low-density lipoprotein (LDL) promotes atherosclerosis by delivering cholesterol to artery-wall macrophages, HDL's cardioprotective effects are mediated in part by the so called reverse cholesterol transport that represents its ability to remove cholesterol from macrophages in a centripetal movement from peripheral tissues, including the vessel wall, toward the liver for biliary secretion (2) .
The failure of HDL-raising drugs, such as niacin and more recently cholesteryl ester transfer protein (CETP) inhibitors (3) , has shown that steady-state HDL cholesterol levels do not represent the most appropriate cardiovascular risk factor index (4) . Efflux capacity, the capacity of HDL particles to mediate cholesterol efflux from macrophages, has been established as having a strong inverse association with both carotid intima-media thickness (5) and also with the incidence of cardiovascular events (6, 7) , independently of HDL cholesterol level. Moreover, recent studies suggested that the impaired efflux capacity of HDL particles may also be an independent risk factor for cardiovascular mortality in patients with chronic coronary artery disease (8, 9) . Cholesterol efflux capacity is also a new therapeutic target, and ongoing studies are evaluating innovative therapies trying to improve cholesterol efflux, thus reducing plaque burden and improving plaque stabilization rather than raising HDL alone (10).
The prevailing system measuring HDL efflux capacity that uses mouse macrophages and apolipoprotein B (apoB)-depleted serum is associated with its own limits, mostly inherent in the use of nonhuman macrophages (11) (12) (13) (14) and nonconsideration of roles of both apoB lipoproteins (15) and CETP (16) in maintenance of cholesterol flow through the intravascular reverse cholesterol transport process (Figure 1 ). In this context, we developed a more comprehensive assay measuring the overall capacity of a given serum to mediate cholesterol efflux from macrophages and have demonstrated its relevance as a clinical tool for identification of patients at high risk of premature atherosclerosis (17) . In the present study, we evaluated for the first time to our knowledge whether serum cholesterol efflux capacity has an independent prognostic value for all-cause mortality in patients hospitalized for an acute myocardial infarction (MI) and treated with primary percutaneous coronary intervention (PCI). In the absence of direct contact with the patient, survival status was checked in the birth city hall registry.
METHODS
STUDY ENDPOINT AND OBJECTIVES. The primary endpoint of the study was all-cause mortality evaluated for the entire study population at 6 years with a minimum of 1 year for the last patients included. cholesterol-loaded human THP-1 macrophages cell line as previously described (17, 19, 20) . 3 (Figure 4) .
DISCUSSION
This study demonstrates for the first time to our knowledge that serum cholesterol efflux capacity, Abbreviations as in Table 1 .
Guerin et al. Numerous human studies support the concept that a reduction of CETP activity, a protein with a key role in reverse cholesterol transport and HDL remodeling (17) , could prevent atherosclerosis (23) . However, the inability of CETP inhibitors to decrease cardiovascular outcomes (24) (25) (26) may suggest that a residual CETP activity should be maintained in order to preserve its optimal physiological action (27) . In our work, we found that reduced CETP activity was not There is no gold standard method for ex vivo evaluation of cholesterol efflux capacity, and considerable differences do exist between research groups (11, 28 (6) or mortality (8) . However, we believe that this is compensated by the fact that our population is on average 20 years older than the population-based cohort previously studied (6, 8) , that the long followup and high event rate of our homogeneous post-MI population is quite high, providing sufficient power to conduct our analysis with multiple adjustments.
Second, data on secondary cardiovascular events HRs for continuous variables are per 1-SD increase. Abbreviations as in Figure 3 . 
